• 
  Thomas Aparicio, Michel Ducreux, Roger Faroux, Emilie Barbier, Sylvain Manfredi, et al.. Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials. European Journal of Cancer, 2018, 98, pp.1 - 9. ⟨10.1016/j.ejca.2018.03.031⟩. ⟨hal-04494820⟩
• 
  Kevin Atsou, Anne Auperin, Jôel Guigay, Sébastien Salas, Sébastien Benzekry. Mechanistic Learning for Predicting Survival Outcomes in Head and Neck Squamous Cell Carcinoma. CPT: Pharmacometrics and Systems Pharmacology, 2024, ⟨10.1002/psp4.13294⟩. ⟨hal-04558029v2⟩
• 
  Cédric Rossi, Guillaume Manson, Amira Marouf, Aurélie Cabannes-Hamy, Emmanuelle Nicolas-Virelizier, et al.. Classic Hodgkin Lymphoma: The LYSA pragmatic guidelines. European Journal of Cancer, 2024, European Journal of Cancer, 213, pp.115073. ⟨10.1016/j.ejca.2024.115073⟩. ⟨hal-04851826⟩
• 
  Dorian Culié, Quentin Lisan, Charlotte Leroy, Anouchka Modesto, Renaud Schiappa, et al.. Oropharyngeal cancer: First relapse description and prognostic factor of salvage treatment according to p16 status, a GETTEC multicentric study. European journal of cancer, 1970, 143, pp.168-177. ⟨10.1016/j.ejca.2020.10.034⟩. ⟨hal-03618860⟩
• 
  Nicolas Penel, Olivier Mir, Jennifer Wallet, Isabelle Ray-Coquard, Axel Le Cesne, et al.. A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib. European Journal of Cancer, 2020, 126, pp.45-55. ⟨10.1016/j.ejca.2019.12.001⟩. ⟨hal-03623680⟩
• 
  Ronald Boellaard, Irène Buvat, Christophe Nioche, Luca Ceriani, Anne-Ségolène Cottereau, et al.. International Benchmark for Total Metabolic Tumor Volume Measurement in Baseline 18 F-FDG PET/CT of Lymphoma Patients: A Milestone Toward Clinical Implementation. Journal of Nuclear Medicine, 2024, 65 (9), pp.1343-1348. ⟨10.2967/jnumed.124.267789⟩. ⟨inserm-04783144⟩
• 
  Simon Baldacci, Benjamin Besse, Virginie Avrillon, Bertrand Mennecier, Julien Mazieres, et al.. Lorlatinib for advanced anaplastic lymphoma kinase–positive non–small cell lung cancer: Results of the IFCT-1803 LORLATU cohort. European Journal of Cancer, 2022, 166, pp.51-59. ⟨10.1016/j.ejca.2022.01.018⟩. ⟨hal-04728569⟩
• 
  J. Guigay, C. Ortholan, D. Vansteene, D. Cupissol, C. Even, et al.. Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial. The Lancet. Healthy longevity, 2024, 5 (3), pp.e182--e193. ⟨10.1016/s2666-7568(23)00284-2⟩. ⟨hal-04661312⟩
• 
  Juliette Thariat, Florent Carsuzaa, Arnaud Beddok, Sophie Deneuve, Pierre-Yves Marcy, et al.. Reconstructive flap surgery in head and neck cancer patients: an interdisciplinary view of the challenges encountered by radiation oncologists in postoperative radiotherapy. Frontiers in Oncology, 2024, 14, pp.1379861. ⟨10.3389/fonc.2024.1379861⟩. ⟨hal-04564034⟩
• 
  Joël Guigay, Hervé Le Caer, François-Régis Ferrand, Lionel Geoffrois, Esma Saada-Bouzid, et al.. Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial. The Lancet. Healthy longevity, 2024, 5 (6), pp.e392-e405. ⟨10.1016/S2666-7568(24)00048-5⟩. ⟨hal-04578230⟩
• 
  Francois Gouin, Audrey Michot, Mehrdad Jafari, Charles Honoré, Jean Camille Mattei, et al.. Improved metastatic-free survival after systematic re-excision following complete macroscopic unplanned excision of limb or trunk soft tissue sarcoma. Cancers, 2024, 16 (7), pp.1365. ⟨10.3390/cancers16071365⟩. ⟨hal-04653665⟩
• 
  Rayan Kabirian, Maria Alice Franzoi, Julie Havas, Charles Coutant, Olivier Trédan, et al.. Chemotherapy-Related Amenorrhea and Quality of Life Among Premenopausal Women With Breast Cancer. JAMA Network Open, 2023, 6 (11), pp.e2343910. ⟨10.1001/jamanetworkopen.2023.43910⟩. ⟨hal-04765786⟩
• 
  Marion Alcantara, Marion Chevrier, Fabrice Jardin, Anna Schmitt, Caroline Houillier, et al.. Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients. Journal of Hematology and Oncology, 2024, 17 (1), pp.86. ⟨10.1186/s13045-024-01606-w⟩. ⟨hal-04719756⟩
• 
  Marcela Carausu, Matthieu Carton, Luc Cabel, Anne Patsouris, Christelle Levy, et al.. Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database. Therapeutic Advances in Medical Oncology, 2022, 14, pp.175883592210770. ⟨10.1177/17588359221077082⟩. ⟨hal-03867853⟩
• 
  Timothy Rebbeck, Tara Friebel, Eitan Friedman, Ute Hamann, Dezheng Huo, et al.. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Human Mutation, 2018, 39 (5), pp.593-620. ⟨10.1002/humu.23406⟩. ⟨hal-02351570⟩
• 
  Thi Khuyen Le, Victor Comte, Jacques Darcourt, Micheline Razzouk-Cadet, Anne-Capucine Rollet, et al.. Performance and Clinical Impact of Radiomics and 3D-CNN Models for the Diagnosis of Neurodegenerative Parkinsonian Syndromes on 18F-FDOPA PET. Clinical Nuclear Medicine, In press, 49 (10), pp.924-930. ⟨10.1097/rlu.0000000000005392⟩. ⟨hal-04682405⟩
• 
  J.Y. Blay, N. Penel, T. Valentin, P. Anract, F. Duffaud, et al.. Improved nationwide survival of sarcoma patients with a network of reference centers. Annals of Oncology, 2024, 35 (4), pp.351-363. ⟨10.1016/j.annonc.2024.01.001⟩. ⟨inserm-04658953⟩
• 
  Emeric Boisteau, Eric François, Thomas Aparicio, Karine Le Malicot, Rabia Boulahssass, et al.. SOCRATE-PRODIGE 55 trial: A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advanced gastric cancer. Digestive and Liver Disease, 2022, 54 (6), pp.747-754. ⟨10.1016/j.dld.2022.03.001⟩. ⟨hal-03632563⟩
• 
  C. Courtinard, V. Barbet, R. Schiappa, F. Pilleul, S. Michiels, et al.. Real-world effectiveness of post-trastuzumab emtansine treatment for human epidermal growth factor receptor 2-positive metastatic breast cancer: a multicenter, matched cohort analysis from the Epidemiology Strategy and Medical Economics database (2008-2018). ESMO Real World Data and Digital Oncology, 2024, 4, pp.100043. ⟨10.1016/j.esmorw.2024.100043⟩. ⟨inserm-04642250⟩
• 
  Emeline Tabouret, François Bertucci, Jean-Yves Pierga, Thierry Petit, Christelle Levy, et al.. MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study. Oncotarget, 2016, 7 (14), pp.18531-18540. ⟨10.18632/oncotarget.7612⟩. ⟨hal-03623733⟩

152

197